SCHEMBL4333044

SCHEMBL4333044

Cc1ccc(NC(=O)c2nc(CN3CCS(=O)(=O)CC3)c3ccccn23)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.66
CNR2 P34972 5/20 0.66
RAB9A P51151 6/20 0.40
NPC1 O15118 6/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HCRTR1 O43613 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333051 0.93 CNR1 (0.56) CNR1CNR2RAB9ANPC1SMN1; SMN2
SCHEMBL4334783 0.89 CNR1 (0.66) CNR1CNR2RAB9ANPC1SMN1; SMN2
SCHEMBL13578119 0.89 CNR2 (0.63) CNR1CNR2RAB9ANPC1ALDH1A1
SCHEMBL4336060 0.88 CNR2 (0.68) CNR1CNR2RAB9ANPC1SMN1; SMN2
SCHEMBL4327707 0.87 CNR1 (0.73) CNR1CNR2RAB9ANPC1GAA
SCHEMBL4324246 0.87 CNR1 (0.63) CNR1CNR2KMT2AMEN1
SCHEMBL4324652 0.87 CNR2 (0.73) CNR1CNR2RAB9ANPC1LMNA
SCHEMBL4331203 0.86 CNR1 (0.65) CNR1CNR2RAB9ANPC1SMN1; SMN2
SCHEMBL4325260 0.85 CNR1 (0.66) CNR1CNR2MAPTLMNA
SCHEMBL4334731 0.85 CNR1 (0.76) CNR1CNR2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 CNR1 2/4885CNR2 1/4885RAB9A 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.